Inhibrx reports FY2025 net loss $140.1M; cash $124.2M plus $75M debt draw

Inhibrx Biosciences, Inc.

Net loss FY2025: $140.1M ($9.04/share), vs FY2024 net income $1.7B from 101 Transaction gain.
Cash $124.2M at Dec 31, 2025; received $75M gross proceeds from Oxford Finance on Mar 18, 2026.
R&D expense $113M (down 44% YoY); G&A $23.3M (down 82% YoY) due to lower clinical costs and prior-year transaction expenses.
ozekibart BLA submission for chondrosarcoma expected early Q2 2026; PFS data for CRC expansion Q2 2026.
INBRX-106: interim ORR data from Phase 2/3 HNSCC trial expected Q2 2026; PFS data at ESMO Q4 2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Inhibrx Biosciences, Inc. reported the fourth quarter and fiscal year 2025 results: net income Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1.

Period: the fourth quarter and fiscal year 2025
Net income: Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1
Result: reported results

Exact text from the filing

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Inhibrx Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0002007919-26-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.